SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR announced today that their next-generation imaging solution with isotropic 3D resolution, SyMRI 3D, has obtained approval in the EU and is now CE-Marked. With preparations in place, SyntheticMR eagerly anticipates the commercial launch of SyMRI 3D at the start of 2024.

“We are delighted to see our 3D solution CE-marked and available on the European market,” says Ulrik Harrysson, CEO at SyntheticMR AB. “SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics.”

SyntheticMR’s new 3D release is a next-generation imaging solution that is poised to revolutionize the field of medical imaging by introducing a myriad of innovative applications within SyMRI’s post-processing solution. This advanced SyMRI sequence introduces 3D resolution to quantitative values and tissue segmentations, ensuring the same level of precision in quantification as achieved with SyMRI’s 2D imaging.

SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function. Furthermore, the exceptional resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions.

“This advanced sequence extends 3D resolution to quantitative values and tissue segmentations, matching the precision achieved in SyMRI’s 2D imaging. The CE-marking for SyMRI 3D paves the way for physicians to make more informed decisions through quantitative imaging.” says Kyle Frye, CCO & President of SyntheticMR Inc. “Receiving approval for SyMRI 3D will allow us to enable physicians to make better, more informed decisions using quantitative imaging.”

The CE mark qualification for SyMRI 3D signifies a monumental stride for SyntheticMR, reaffirming its commitment to transforming medical imaging.

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-12-2023 10:00 CET.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers. Our aim is to make Perimeter's innovative technology the standard of care in cancer surgery."

By using this website you agree to accept Medical Device News Magazine Privacy Policy